3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
11
Specimen Handling
4
X-Rays
3
Nivolumab
3
Ipilimumab
3
Immunoglobulin G
3
Biopsy
3
temsirolimus
2
sargramostim
2
epacadostat
2
capivasertib
2
Taxes
2
Paclitaxel
2
Metformin
2
Magnetic Resonance Spectroscopy
2
Disulfides
2
Cyclophosphamide
2
Blood Specimen Collection
2
zimberelimab
1
veliparib
1
ulixertinib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
toripalimab
1
spartalizumab
1
sonidegib
1
sapanisertib
1
relatlimab
1
pertuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Technetium-99
×
Dermatologic
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled